John Kastelein

Dr. Kastelein (1954) is Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he held the Strategic Chair of Genetics of Cardiovascular Disease. Professor Kastelein has published over 1320 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 122 in January 2020. His citations reached over 680 in 2020 and in total over 74800.

John J.P. Kastelein is currently the CSO of New Amsterdam Pharma, a company developing Obicetrapib, a CETP inhibitor,that lowers LDL-cholesterol ands apoB and reduces CV risk. He is also the acting chief medical officer (CMO) of Statin Biotechnology Inc., a company developing a monoclonal antibody (Mab) against apolipoprotein CIII and he holds a Board position in North Sea Therapeutics, a company involved in NASH and cardiometabolic therapeutics. Dr. Kastelein is chief executive officer (CEO) of the Vascular Resesarch Network (VRN), a site maintenance organization comprising over 50 hospitals in the Netherlands, involved in clinical trials for cardiometabolic disease. Next to these functions, Dr. Kastelein is key advisor to a number of biotech and pharmaceutical companies.